Related Experiment Videos
Low-molecular-weight heparins during pregnancy
1Tel Aviv Medical Center, Tel Aviv University, Israel.
Canadian Family Physician Medecin De Famille Canadien
|March 9, 2005
Summary
Dalteparin, a low-molecular-weight heparin (LMWH), is a safe and convenient alternative to traditional heparin during pregnancy. Evidence suggests LMWHs offer comparable safety for both mothers and fetuses.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Thrombosis Management
Background:
- Pulmonary embolism is a serious complication during pregnancy.
- Traditional unfractionated heparin has been the standard anticoagulant therapy.
- Patient preference and physician recommendations may influence treatment choices.
Purpose of the Study:
- To compare the safety and efficacy of dalteparin with heparin during pregnancy.
- To evaluate dalteparin as an alternative anticoagulant for pregnant patients with a history of thromboembolism.
Main Methods:
- Review of existing literature including prospective case series, retrospective reports, and placental perfusion studies.
- Analysis of safety and convenience data for low-molecular-weight heparins (LMWHs) in pregnant populations.
Main Results:
- Low-molecular-weight heparins, exemplified by dalteparin, demonstrate safety in pregnancy.
- Dalteparin offers a convenient alternative to thrice-daily heparin injections.
Conclusions:
- Dalteparin is a safe and convenient alternative to heparin for pregnant individuals.
- Evidence supports the use of LMWHs for anticoagulation during pregnancy, benefiting both mother and fetus.